Aequus Announces Giovanni Di Genova Joining Board of Directors

Company Overview - Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on commercializing value-added products in specialty therapeutic areas within the Canadian market [3]. New Appointment - Giovanni Di Genova has been appointed to the Aequus Board of Directors, effective September 12th, 2025, pending completion of his PIF and TSX approval [1][2]. - Doug Janzen, Aequus Chairman & CEO, expressed enthusiasm about working with Giovanni Di Genova on future initiatives [2]. Giovanni Di Genova's Background - Giovanni Di Genova holds a Bachelor of Science and a Bachelor of Pharmacy from McGill University and Université de Montréal, respectively [2]. - He has nearly 35 years of experience in the specialty compounding pharmacy and pharmaceutical industry, covering various therapeutic areas such as ophthalmology, oncology, gastrointestinal, neurological, infectious, and autoimmune diseases [2]. - Di Genova has held multiple roles in both innovative and generic pharmaceutical organizations, with a strong background in strategy, operations, business development, M&A, licensing, co-development, and supply agreements [2].